Selumetinib (AZD6244 hyd sulfate) 50mg/dose

( DrugBank: Selumetinib, Sulfate / KEGG DRUG: Selumetinib )

1 disease

ID	Disease name (Link within this page)	Number of trials
34	Neurofibromatosis	1

34. Neurofibromatosis

Clinical trials : 133 / Drugs : 186 - (DrugBank : 67) / Drug target genes : 79 - Drug target pathways : 190

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03109301 (ClinicalTrials.gov)	April 7, 2017	11/4/2017	Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in ...	A Phase II Trial of the Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6 ...	Neoplasms, Nerve Tissue;Neurofibromatosis 1;Heredodegenerative Disorders, Nervous System;Peripheral ...	Drug: Selumetinib (AZD6244 hyd sulfate) 50mg/dose;Drug: Selumetinib (AZD6244 hyd sulfate) 25mg/m2	National Cancer Institute (NCI)	NULL	Withdrawn	3 Years	99 Years	All	0	Phase 2	United States

First Previous1Next Last